ReCatalyst’s Post

One unique way that RWI Synthetics engages with regions, clients, and community leaders is through sponsored synthetic environments. Funded by a champion, these synthetic twins of a region are available for more than just strategic engagements or advanced lab groups. They offer sponsors an opportunity to gain recognition as regional leaders in economic prosperity, equity, resilience, and community building. By guiding and informing the future of a region, sponsors become an integral part of the regional development process. RWI Synthetics’ world-first Synthetic Twin collaborative, the Regional Edmonton Advanced Lab (REAL), is a subscription-based, theme-driven convergence of diverse community stakeholders. As regions grow and become more complex and face mounting acute and chronic events, the people, scenario, and place-based intelligence of Synthetic Twins enable new analytics and insights to support leaders facing interconnected, human-centric futures. Successful investments must be generational and address equity, resilience, and sustainability. Synthetic Calgary is a collaborative future design of the Calgary Region. It is a platform to discuss, explore, evaluate and inflect the future impact of today’s biggest decisions. It sets forth considerations for the region’s future and the implications of today's policy, investment, and equity decisions. This unique platform allows leaders to make complex decisions faster, more equitably, and with more confidence than ever before, thereby shaping the future of the Calgary Region. #Sponsored #SyntheticEnvironment #SyntheticTwins #StrategicEngagements

🎉 Abselion Secures £6.6M Series A to Revolutionise Protein Quantitation! Exciting news in bioprocessing! Abselion has raised £6.6M ($8.4M) in Series A funding to commercialise its Amperia system, powered by proprietary Redox Electrochemical Detection (RED) technology. This benchtop marvel provides real-time protein quantitation directly from crude samples in under a minute, speeding up processes that typically take days. 💡 Key Highlights: Backed by M Ventures (Merck’s VC arm), BioProcess360 Partners , and other top investors. Amperia is designed to deliver gold-standard insights for bioprocess optimisation, improving development and manufacturing robustness. New board members: Oliver Hardick (M Ventures) & Chris Major (BioProcess 360 Partners). Abselion CEO Ruizhi Wang celebrates the milestone, emphasising the system’s impact on real-time decision-making for scientists. #BiotechInnovation #ProteinAnalysis #SeriesAFunding #Bioprocessing #Abselion #AmperiaSystem #RealTimeData

Attending the UASEED Market Discovery Workshop was an incredibly enlightening experience. David Gunnarsson, CTO of Bluefors, shared valuable insights on the significance of market entry and strategic growth. Here are some key takeaways from his presentation: 🌿 Company Growth Being in the right place at the right time is crucial for growth. Bluefors, founded in 2008, has grown to over 600 professionals from over 50 nationalities, with more than 1,000 systems installed worldwide. 🌿 Unique Product Bluefors’ ultra-low temperature cryogenic measurement systems are designed for quantum technology and other scientific uses. Their core products, Dilution Refrigerators and Cryocoolers, cater to large corporations, universities, research labs, and startups. 🌿 Market Entry Entering a high-threshold market requires a unique product. Bluefors overcame challenges in cryogenics by creating reliable, easy-to-use systems with scalable production. 🌿 Innovation and Support Bluefors supports scientists and industries to drive future innovation, providing scalable production and an industrial supply chain for cryogenics. 🌿 Challenges and Solutions Around 16 years ago, the cryogenics field faced problems like unreliability, size constraints, and scaling issues. Bluefors addressed these with fully automated, user-friendly designs that required only basic lab infrastructure. Bluefors’ story is truly inspiring. We are researching similar success stories to achieve success in external markets and learn from their examples. #MarketEntry #BusinessGrowth #Innovation #Cryogenics #QuantumTechnology

🤝 We’re joining forces with I-Corps Hub Northeast Region and Nucleate Philly for the next installment of the Innovating Together Series. 💡Come learn about how we work with the National Science Foundation (NSF) I-Corps Hub Northeast Region to accelerate impactful academic bioventures. Whether you're far along in your commercialization journey or just starting out and wanting to learn more about innovation, all are welcome! 🗽We will share details on our regional program & events and will join a discussion about how innovators and I-Corps teams can participate in the Activator Programs. Panelists include: 1. Robert Trudeau, Managing Director of Nucleate Philadelphia 2. Harshit Harpaldas Chellani, Managing Director of Nucleate New York 📆Friday October 25th, 11 AM ⭐Register here: https://loom.ly/Mh5STGs Applications are open for the upcoming Novus and regional Propelus I-Corps Programs through Fall 2024. Teams of 2+ exploring the commercial potential of innovation are invited to apply to Propelus, and individuals and teams are welcome to attend Novus. ⭐ https://loom.ly/tuTNRxY 📅Application deadline for the Nucleate Activator program has been extended to November 6th, 2024. 🔗 Apply here: apply.nucleate.org 🌐 Learn more: nucleate.org/activator #biotech #innovation #startup #icorp #nsf #commercialization #accelerator

Private funding, intellectual property and science equity have been identified as key elements to incentivize European competitiveness. At Fractus, we are proud to have participated in the event organised by BeAble Capital SGEIC SA and PONS IP . 💡💼 Our CEO and co-founder, Rubén Bonet, has highlighted that the current system works very well for financing the R+D. However, when the objective is to launch a new business it is important to consider the equity science as well. In addition to Rubén, the panel was formed by prominent profiles such as Almudena Trigo Lorenzo, Founding Partner of BeAble Capital; Alberto Díaz González, Partner of BeAble Capital; Nuria Marcos, Managing Director of PONS IP; and Belén Linares Corell from CEPSA . 👥 At Fractus, we remain committed to innovation and driving scientific capital - together, we build a brighter future! ✨🔬 #intellectualproperty #ip #deeptech #equityscience #equitycapital #publicfunding #RandD #researchandevelopment #patents #technology

We are pleased to share that Sean Coffey, SVP, Investments will speak next Thursday at Bisnow’s Boston Life Science Conference at the Seaport Hotel. Sean’s panel titled Navigating Funding & Deals Amidst Changing Interest Rates, will provide valuable insight on executing projects amidst challenging capital markets. Other topics covered at this year’s conference are major developments, evolving tenant needs, and how leasing dynamics and innovation hubs are enhancing greater Boston’s biotech ecosystem.   Register here: https://lnkd.in/dnj88-EU   #LifeScienceInvestments #BioTech #GreaterBostonLifeScience #LifeScienceRealEstate

🎉 #Congratulations to Abselion, a Cambridge-based innovator, for raising £6.6 million in Series A funding led by M Ventures ➡️ https://ow.ly/IB3M50UoZ1t 💡 This investment will drive the commercialisation of their pioneering Amperia system, a groundbreaking instrument that enables rapid, at-line protein quantification, setting a new standard in bioprocessing efficiency. 👏 With support from BioProcess 360 Partners, BGF and other notable investors, Abselion is set to deliver significant advancements in bioprocess development and #lifesciences innovation.

🚀 Fortnight ago, the 𝐃𝐞𝐞𝐩𝐭𝐞𝐜𝐡 𝐀𝐭𝐭𝐞𝐥𝐢𝐞𝐫 event took place, bringing together all stakeholders of the deep tech ecosystem: entrepreneurs, scientists and technology developers, investors, government, and public organizations. During the event, the 𝐁𝐈𝐎𝐂𝐎𝐍𝐍𝐄𝐂𝐓 project was discussed and presented in a panel discussion at the Biocosmic stage. 🗝️ A key highlight was the panel discussion on the “𝐁𝐚𝐥𝐭𝐢𝐜 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐄𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦,” organized by the Biocatalyst Foundation. The discussion featured partners from the 𝐁𝐈𝐎𝐂𝐎𝐍𝐍𝐄𝐂𝐓 project, including Donatas Staniulis representing LithuaniaBIO, Igors Berkovics from the Biocatalyst Foundation, and other discussion participants such as Emilio Parisini, ERA Chair, Biotechnology Group, Latvian Institute of Organic Synthesis, and Janis Locs, Director at RTU Institute of Biomaterials and Bioengineering and Baltic Biomaterials Centre of Excellence. 🌍 The discussion explored the biotechnology ecosystem across the Baltic states—Lithuania, Latvia, and Estonia. Topics included the collaborative environment, challenges, and the role of the 𝐁𝐈𝐎𝐂𝐎𝐍𝐍𝐄𝐂𝐓 project in unifying the biotech ecosystem. 🙌 Stay tuned for more updates and developments about the 𝐁𝐈𝐎𝐂𝐎𝐍𝐍𝐄𝐂𝐓 project and its impact on the Baltic biotech sector. #DeeptechAttelier #Biotechnology #Bioconnectproject #BalticBiotech #Collaboration

💡 Driving Innovation in Life Science Manufacturing! 🌍 ⏩ Check out our #13 BioMan4R2 Success Story! At BioMan4R2, we are proud to see the incredible impact our 𝙄𝙉𝙉𝙊𝙑𝘼𝙏𝙄𝙊𝙉 𝙁𝙄𝙉𝘼𝙉𝘾𝙄𝘼𝙇 𝙎𝙐𝙋𝙋𝙊𝙍𝙏  is having on companies like PolyAn GmbH! 🚀 PolyAn GmbH, a leader in the life science industry, specializes in supplying high-end consumables like functionalized slides, coverslips, and membranes, which are essential for biomedical and biochemical research. 🔬 Thanks to the support from #BioMan4R2, PolyAn is tackling a major challenge: translating manual production processes into automated systems—a game-changer for their operations! 🔧 What does this mean? With automation, PolyAn is: ✅ Boosting efficiency by making processes more resilient and robust ⚙️ ✅Increasing scalability to meet the growing demands of the life science industry 📈 ✅Continuing to deliver the highest quality in their production of surface coatings for life science research 🧬 This marks a major milestone not only for #PolyAn but for the entire #European life science ecosystem as they pioneer automation solutions that were previously unavailable. 💪 🎉Congratulations PolyAn GmbH on your achievements! 🎉 Fridtjof Lechhart Maiko Schulze Dr. Karl-Ulrich Schellhaas       We’re thrilled to be part of #PolyAn’s journey towards innovation and excellence in automated manufacturing, and look forward to more success stories from our program! 🌟 #BioMan4R2 #LifeSciences #ProcessAutomation #Innovation #Biotech #ManufacturingExcellence #PolyAn #EUInnovation #BiomedicalResearch